GlobeNewswire
-
Landmark Living Brain Study Published in CELL Identifies a Novel Molecular Roadmap Governing Human Brain Aging
02/02/2026 -
Groundbreaking therapy for advanced heart failure
02/02/2026 -
Thérapie révolutionnaire pour l’insuffisance cardiaque avancée
02/02/2026 -
Agomab Announces Launch of Initial Public Offering
02/02/2026 -
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026 -
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026 -
Quotient Therapeutics Appoints Seasoned Life Sciences Executive, Susan Keefe, as Chief Financial Officer
02/02/2026 -
Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
02/02/2026 -
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
02/02/2026 -
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
02/02/2026 -
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
02/02/2026 -
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
02/02/2026 -
MIMEDX Celebrates 15 Year Anniversary of EPIFIX® and AMNIOFIX®
02/02/2026 -
DLH to Announce Fiscal 2026 First Quarter Financial Results
02/02/2026 -
Arcutis Announces Positive Topline Results for INTEGUMENT-INFANT Phase 2 Trial of ZORYVE® (roflumilast) Cream 0.05% in Infants with Mild to Moderate Atopic Dermatitis
02/02/2026 -
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
02/02/2026 -
Join ProPhase Labs’ Exclusive Live Investor Webinar and Q&A Session on February 3rd
02/02/2026 -
Abinopharm, Inc. Releases AbinoNutra® NMN White Paper Following FDA Reinstatement and Human Clinical Trial Evidence
02/02/2026 -
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
02/02/2026
Pages